ArcherDx, HeliTec Partner on Cancer Dx Development

Apr 04, 2017

|

NEW YORK (GenomeWeb) – ArcherDx has partnered with HeliTec on the development of next-generation sequencing-based cancer diagnostics for the Chinese market, the companies announced today.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

ArcherDx, HeliTec Partner on Cancer Dx Development

To read the full story....

Breaking News

Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor

FDA Grants First ASCA Accreditations to Labs to Perform Premarket Testing

Top Five Articles on 360Dx Last Week: NIH RADx, LumiraDx, Abbott, And More

Amazon to Give Out $12M Under Next Phase of AWS Diagnostics Development Initiative

Lucira Health Nabs OTC EUA for SARS-CoV-2 Test, Expects Q1 Revenues of up to $4.5M

DiaSorin to Acquire Luminex for $1.8B

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

What's Popular?

Abcam, MEDx Expand Cancer Diagnostics Development Alliance

Armed With $55M in New Funding, Nucleix to Further Invest in Early-Stage Lung Cancer Dx

Roche Elecsys Anti-p53 Test for Cancer Diagnosis Earns CE Mark

Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor

Sponsorships